Overexpression of the Notch3 receptor and its ligand Jagged1 in human clinically non-functioning pituitary adenomas

Human clinically non-functioning pituitary adenomas (NFPAs) primarily cause headaches, visual impairment and hypopituitarism due to the effect of the mass of the tumor. Surgery is the first-line treatment for these tumors. To date, no efficacious medical therapy exists for non-functioning adenomas. Previous studies have demonstrated that the Notch3 receptor is involved in the pathogenesis of various types of malignancies, including human NFPAs. The current study focused on the expression of the Notch3 receptor and its ligand Jagged1 in three types of pituitary adenomas and in the normal pituitary gland. Using quantitative real-time RT-PCR assays and western blot analyses, upregulated Notch3 and Jagged1 were observed in human NFPAs, but not in normal human pituitary glands or in hormone-secreting adenomas. Furthermore, Notch3 was positively correlated with Jagged1 at the mRNA and protein levels. These data indicate that Notch3 and Jagged1 may play an important role in the initiation and proliferation of human non-functioning adenomas, and there may be an interaction between Notch3 and Jagged1 in this process. Our study further elucidates the role of the Notch3 signaling pathway in the tumorigenesis of human NFPAs and provides a potential therapeutic target for the medical treatment of these tumors.

[1]  S. Ansell,et al.  MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma , 2012, Leukemia.

[2]  Yifeng Miao,et al.  Overexpression of the Notch3 receptor in non-functioning pituitary tumours , 2012, Journal of Clinical Neuroscience.

[3]  A. Krešo,et al.  Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer , 2012, Oncogene.

[4]  L. Raetzman,et al.  Persistent expression of activated Notch inhibits corticotrope and melanotrope differentiation and results in dysfunction of the HPA axis. , 2011, Developmental biology.

[5]  A. Harris,et al.  Notch3 signalling promotes tumour growth in colorectal cancer , 2011, The Journal of pathology.

[6]  A. Sood,et al.  Targeting the Notch Ligand Jagged1 in Both Tumor Cells and Stroma in Ovarian Cancer , 2011, Clinical Cancer Research.

[7]  G. Basso,et al.  Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells , 2011, Leukemia.

[8]  A. Klein-Szanto,et al.  NOTCH1 and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent transcriptional network. , 2010, Gastroenterology.

[9]  Tian-Li Wang,et al.  Jagged1 Expression Regulated by Notch3 and Wnt/β-catenin Signaling Pathways in Ovarian Cancer , 2010, Oncotarget.

[10]  S. Indraccolo,et al.  Ligand-driven activation of the Notch pathway in T-all and solid tumors: Why Not(ch)? , 2010, Cell cycle.

[11]  C. Kenific,et al.  Down‐regulation of the Notch pathway mediated by a γ‐secretase inhibitor induces anti‐tumour effects in mouse models of T‐cell leukaemia , 2009, British journal of pharmacology.

[12]  Y. Greenman,et al.  Non-functioning pituitary adenomas. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[13]  T. Dang,et al.  Notch3 Cooperates With the EGFR Pathway to Modulate Apoptosis Through The Induction Of Bim , 2009, Oncogene.

[14]  L. Raetzman,et al.  The notch target gene HES1 regulates cell cycle inhibitor expression in the developing pituitary. , 2009, Endocrinology.

[15]  S. Savastano,et al.  Medical therapy of pituitary adenomas: Effects on tumor shrinkage , 2009, Reviews in Endocrine and Metabolic Disorders.

[16]  N. López-Bigas,et al.  Jagged1 is the pathological link between Wnt and Notch pathways in colorectal cancer , 2009, Proceedings of the National Academy of Sciences.

[17]  M. Korbonits,et al.  Recent Clinical and Pathophysiological Advances in Non-Functioning Pituitary Adenomas , 2009, Hormone Research in Paediatrics.

[18]  A. Faggiano,et al.  Medicaltherapyforclinicallynon-functioning pituitary adenomas , 2008 .

[19]  I. Shih,et al.  Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. , 2008, Cancer research.

[20]  M. Westerfield,et al.  Notch signaling regulates endocrine cell specification in the zebrafish anterior pituitary. , 2008, Developmental biology.

[21]  Shinya Watanabe,et al.  NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. , 2008, Cancer research.

[22]  C. Moreno,et al.  Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses , 2008, Pituitary.

[23]  T. Dang,et al.  Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. , 2007, Cancer research.

[24]  T. Ohtsuka,et al.  Hes1 and Hes5 control the progenitor pool, intermediate lobe specification, and posterior lobe formation in the pituitary development. , 2007, Molecular endocrinology.

[25]  I. Shih,et al.  Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy: Figure 1. , 2007 .

[26]  Michael Buchfelder,et al.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. , 2007, European journal of endocrinology.

[27]  C. Jaffe.  Clinically non-functioning pituitary adenoma , 2006, Pituitary.

[28]  R. Kageyama,et al.  Sustained Notch signaling in progenitors is required for sequential emergence of distinct cell lineages during organogenesis. , 2006, Genes & development.

[29]  Tian-Li Wang,et al.  Notch3 gene amplification in ovarian cancer. , 2006, Cancer research.

[30]  L. Miele,et al.  NOTCH signaling as a novel cancer therapeutic target. , 2006, Current cancer drug targets.

[31]  A. Federico,et al.  Physiology and pathology of notch signalling system , 2006, Journal of cellular physiology.

[32]  W. Saeger,et al.  Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. , 2006, European journal of endocrinology.

[33]  I. Screpanti,et al.  Notch3 and pre‐TCR interaction unveils distinct NF‐κB pathways in T‐cell development and leukemia , 2006, The EMBO journal.

[34]  Xianquan Zhan,et al.  Novel molecular signaling and classification of human clinically nonfunctional pituitary adenomas identified by gene expression profiling and proteomic analyses. , 2005, Cancer research.

[35]  T. Giordano,et al.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. , 2005, Cancer cell.

[36]  T. Dang,et al.  Dominant-negative Notch3 receptor inhibits mitogen-activated protein kinase pathway and the growth of human lung cancers. , 2005, Cancer research.

[37]  H. Stein,et al.  Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. , 2004, Blood.

[38]  Eric C. Lai,et al.  Notch signaling: control of cell communication and cell fate , 2004, Development.

[39]  D. Desiderio,et al.  The human pituitary proteome: the characterization of differentially expressed proteins in an adenoma compared to a control. , 2003, Cellular and molecular biology.

[40]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[41]  U. Lendahl,et al.  Constitutive activation of NF‐κB and T‐cell leukemia/lymphoma in Notch3 transgenic mice , 2000, The EMBO journal.

[42]  M. Korbonits,et al.  Cyclin D and cyclin E expression in normal and adenomatous pituitary. , 2000, European journal of endocrinology.

[43]  S. Artavanis-Tsakonas,et al.  Notch Signaling : Cell Fate Control and Signal Integration in Development , 1999 .

[44]  I. Greenwald,et al.  LIN-12/Notch signaling: lessons from worms and flies. , 1998, Genes & development.

[45]  N. Gittoes.  Current perspectives on the pathogenesis of clinically non-functioning pituitary tumours. , 1998, The Journal of endocrinology.

[46]  A. Klibanski,et al.  Clinical review 45: Clinically nonfunctioning pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[47]  P. Black,et al.  Hormone production in clinically nonfunctioning pituitary adenomas. , 1987, Journal of neurosurgery.

[48]  Tian-Li Wang,et al.  Notch signaling, gamma-secretase inhibitors, and cancer therapy. , 2007, Cancer research.